CSI Market
Sign In | Register

Immucell (ICCC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ICCC quarterly Cash Flow →
Cash flow patterns shown here provide context for understanding Immucell's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-1.04
Depreciation & amortization2.71
Amortization of Other Assets0.07
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges2.67
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-2.15
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.11
Share-based Compensation0.30
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Noncash Rent Benefit-0.28
Increase Decrease In Capital Expenditures-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Noncash Rent Expense Benefit0.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.35
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.20
Increase (Decrease) in Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.05
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities2.48
Investing Activities
Capital Expenditures-1.25
Sale of Capital Items0.04
Payments for (Proceeds from) Short-term Investments, Total0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment For Contingent Consideration Liability Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1.21
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.01
Long-term debt - borrowings-2.28
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.76
Tax Benefit From Stock Options Exercised-
Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense-
Proceeds From Repayments Of Debt Issuance Cost-
Tax Benefit From Stock Options Exercised-
Tax Benefits Related To Stock Options-
Payments Of Debt Issuance Cost-
Payments Of Debt Discounts-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents-
Proceeds From Issuance Of Debtnet0.80
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations3.76
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-1.21
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1.26
Total Cash Flow0.05
4 historic quarters locked

Sign in to unlock the full Immucell cash flow history.

Sign In Create Free Account

About Immucell Corp Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001437749-26-010339

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License